Tobidex is indicated for steroid responsive inflammatory ocular conditions for which a corticosteroid is indicated and where superficial bacterial ocular infection or a risk of bacterial ocular infection exists. Ocular steroids are indicated in inflammatory conditions of the palpebral and bulbar conjunctiva, cornea and anterior segment of the globe where the inherent risk of steroid use in certain infective conjunctivitis is accepted to obtain a diminution in edema and inflammation. They are also indicated in chronic anterior uveitis and corneal injury from chemical, radiation or thermal burns, or penetration of foreign bodies. The particular anti-infective drug in this product is active against the following common bacterial eye pathogens: Staphylococci, including S. aureus and S. epidermidis (coagulase-positive and coagulase-negative), including penicillin-resistant stains. Streptococci, including some of the Group A-beta-hemolytic species, some nonhemolytic species and some Streptococcus pneumoniae. Pseudomonas aeruginosa, Escherichea coli, Klebsiella pneumonia, Enterobacter aerogenes, Proteus mirabilis, Morganella morganii, most Proteus vulgaris strains, Haemophilus influenzae and H. aegyptius, Moraxella lacunata, Acinetobacter calcoaceticus and some Neisseria species.

Dosage and administration: Tobidex eye drops: One or two drops instilled into the conjunctival sac(s) every four to six hours. During the initial 24 to 48 hours, the dosage may be increased to one or two drops every two (2) hours. Frequency should be decreased gradually as warranted by improvement in clinical signs. Care should be taken not to discontinue therapy prematurely. Tobidex eye ointment: Apply a small amount (approximately ½ inch ribbon) into the conjunctival sac(s) up to three or four times daily. Presentation: Tobidex ophthalmic suspension: 5ml sterile Eye Suspension in plastic dropper bottle. Tobidex eye ointment: 3.5 g sterile ointment in collapsible tube.